JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Cuproptosis-related gene CEP55 as a biomarker of pancreatic adenocarcinoma via multi-omics techniques and experimental validation

  • 01Department of Hepatobiliary and Pancreatic Surgery, People's Hospital of Pingyang County, Wenzhou, China.
Radiology and Oncology +

|

July 18, 2025

|

July 18, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

This study develops a new prognostic model for pancreatic adenocarcinoma (PAAD) using cuproptosis-related genes. The model identifies CEP55 as a key gene, offering potential new treatment targets for PAAD.

Area Of Science

  • Oncology
  • Molecular Biology
  • Bioinformatics

Background

  • Pancreatic adenocarcinoma (PAAD) presents a significant clinical challenge due to its poor prognosis.
  • The role of cuproptosis in PAAD, especially when integrating single-cell and TCGA data, remains largely unexplored.

Purpose Of The Study

  • To identify cuproptosis-related genes (CRGs) in PAAD.
  • To construct a prognostic model for PAAD based on CRGs.
  • To investigate the relationship between cuproptosis, the tumor immune microenvironment, and patient prognosis.

Main Methods

  • Single-cell analysis and weighted gene co-expression network analysis (WCGNA) to identify CRGs.
  • Cox and LASSO regression analyses using TCGA data to build a prognostic model.
  • Evaluation of the tumor immune microenvironment, mutation analysis, and in vitro experiments to validate the role of CEP55.

Main Results

  • A cuproptosis-related prognostic model was established, differentiating high-risk and low-risk PAAD patient groups with significant survival differences.
  • Higher cuproptosis-related scores correlated with reduced immune infiltration and increased mutation rates, suggesting potential benefits from immunotherapy in high-risk groups.
  • CEP55 was identified as significantly overexpressed in PAAD, linked to poor prognosis, and its knockdown inhibited cancer cell proliferation and invasion.

Conclusions

  • A novel prognostic model for PAAD was developed, aiding in the evaluation of prognosis and immune microenvironment.
  • CEP55 was identified as a crucial gene in PAAD, with in vitro studies confirming its role in cancer progression.
  • The findings offer a new potential therapeutic target for pancreatic adenocarcinoma treatment.

Keywords: